Clinical Trial Update: Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Biocad's monoclonal anti-IL-17 antibody BCD-085 completed a Phase 3 study evaluating efficacy and safety in psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• BCD-085

Snippet

Sponsor: Biocad | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED